Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Advances in alpha-synuclein as a biomarker for Parkinson’s disease

Tiago Outeiro, PhD, University Medical Center Göttingen, Göttingen, Germany, discusses the exciting developments in using alpha-synuclein as a biomarker for the early detection of Parkinson’s disease. Recent studies have shown that a seed amplification assay in cerebrospinal fluid (CSF) samples has high specificity in identifying the presence of alpha-synuclein species associated with Parkisnon’s disease. Additionally, researchers have discovered that a similar assay can be performed on blood and plasma samples, making it a more accessible and less invasive option for screening. These advancements in biomarkers have the potential to greatly aid in patient selection for clinical trials and the development of novel therapies. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.